Key facts
- Notable investors include First Avenue Ventures, Pacific Reach Capital, Ambria Capital, JLS Fund, Negev Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Diamond Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Diamond Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Diamond Therapeutics
Operator of a drug development company intended to work towards new and suitable therapies for mental health conditions by unlocking the promise of psychedelic compounds. The company offers healthcare services like psychopharmacology, biotechnology, life sciences, and neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines, focused on safe, take-at-home treatments that hold potential for use across a broad patient cohort -maximizing the positive impact useful drugs can have on global mental health, enabling patients to deliver current first-line treatments and recover faster.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2018
- Employees
- 8
- Website
- diamondthera.com/
- Ownership
- Privately Held (backing)
Diamond Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Diamond Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Diamond Therapeutics in its N-PORT filings yet. We sweep new filings monthly.